canin
viscer
leishmaniasi
cell
humor
immun
respons
flow
cytometri
vaccin
canin
viscer
leishmaniasi
cvl
compris
leishmania
braziliensi
promastigot
protein
sand
fli
gland
extract
sge
saponin
adjuv
evalu
dog
model
order
analys
immunogen
candid
vaccin
vaccin
candid
elicit
strong
antigen
dog
respect
specif
sge
leishmania
humor
immun
respons
major
saliva
protein
recogn
serum
immun
dog
exhibit
molecular
weight
kda
relat
resist
pattern
leishmania
infect
immunophenotyp
analysi
reveal
increas
circul
bcell
correspond
author
atet
al
tcell
reflect
higher
count
tcell
observ
interact
potenti
antigenpres
cell
evalu
monocyt
lymphocyt
activ
statu
indic
relationship
innat
adapt
immun
respons
higher
frequenc
l
chagasi
antigenspecif
tlymphocyt
posit
associ
intens
cell
prolifer
addit
progress
higher
product
serum
nitric
oxid
level
show
profil
compat
anticvl
vaccin
potenti
studi
immunolog
respons
challeng
l
chagasi
may
provid
import
inform
lead
better
understand
vaccin
trial
efficaci
new
world
sand
fli
lutzomyia
longipalpi
import
vector
leishmania
chagasi
etiolog
agent
viscer
leishmaniasi
vl
act
probe
feed
infect
femal
sand
fli
introduc
host
secret
salivari
gland
fli
promastigot
l
chagasi
known
saliva
l
longipalpi
possess
apyras
anticoagul
vasodilatori
immunomodulatori
activ
could
facilit
evas
inflammatori
immun
respons
host
furthermor
initi
studi
leishmania
major
demonstr
sand
fli
saliva
exacerb
host
infect
similar
find
report
number
differ
speci
leishmania
mice
expos
homogen
salivari
gland
l
longipalpi
bite
uninfect
sand
fli
protect
infect
challeng
either
needleinocul
l
major
plu
sand
fli
saliva
bite
sand
fli
infect
l
major
morri
et
al
report
anim
vaccin
maxadilan
potent
vasodil
immunomodul
l
longipalpi
protect
l
major
infect
addit
mice
vaccin
kda
salivari
protein
sand
fli
immun
infect
l
major
challeng
promastigot
saliva
data
support
hypothesi
induct
immun
respons
salivari
protein
sand
fli
may
facilit
protect
immun
respons
leishmania
infect
although
effect
vaccin
human
canin
viscer
leishmaniasi
cvl
yet
avail
much
effort
expend
area
recent
year
sever
candid
vaccin
antigen
studi
extens
dog
recent
strategi
develop
vaccin
leishmaniasi
base
use
purifi
fraction
parasit
extract
flm
antigen
parasit
cultur
excretedsecret
antigen
frequent
use
saponin
adjuv
encourag
result
report
howev
search
potenti
vaccin
target
singl
protein
might
adequ
approach
select
multipl
protein
candid
may
requir
develop
vaccin
leishmaniasi
strategi
base
combin
sand
fli
salivari
gland
extract
sge
leishmania
antigen
might
appropri
moreov
although
current
strategi
vaccin
leishmaniasi
base
use
recombin
antigen
whole
parasit
vaccin
still
attract
term
cost
safeti
stabil
biochem
composit
antigen
trial
util
vaccin
alreadi
undertaken
sever
studi
involv
dog
model
reveal
crude
antigen
vaccin
elicit
strong
cell
reactiv
leishmania
antigen
unfortun
detail
immun
statu
experiment
anim
follow
sge
vaccin
evalu
within
framework
studi
dog
repres
import
domest
reservoir
l
chagasi
vaccin
cvl
would
import
tool
control
human
vl
decreas
dramat
infect
pressur
l
chagasil
infantum
better
understand
canin
immun
respons
sand
fli
salivari
protein
could
signific
assist
defin
altern
vaccin
strategi
control
cvl
well
human
vl
present
studi
constitut
first
detail
analysi
immunogen
experiment
dog
receiv
promis
cvl
vaccin
compos
kill
l
braziliensi
togeth
saponin
adjuv
sge
detail
studi
present
approv
ethic
committe
use
experiment
anim
universidad
feder
de
mina
gerai
belo
horizontemg
brazil
close
coloni
l
longipalpi
maintain
c
rel
humid
accord
publish
protocol
sge
prepar
use
method
cavalcant
et
al
acini
salivari
gland
mate
nonblood
fed
femal
sand
fli
dissect
unbuff
salin
broken
sonic
centrifug
g
min
supernat
collect
store
c
requir
use
twentyf
mongrel
male
femal
dog
born
rear
kennel
instituto
de
exata
e
universidad
feder
de
ouro
preto
ouro
preto
mina
gerai
brazil
vaccin
age
month
rabi
tecpar
curitibapr
brazil
canin
distemp
type
adenoviru
coronaviru
parainfluenza
parvoviru
leptospira
vanguard
htlp
pfizer
anim
health
new
york
ny
usa
treat
anthelmint
absenc
specif
antileishmania
antibodi
confirm
indirect
fluoresc
immunoassay
ouro
preto
citi
consid
nonendem
area
viscer
leishmaniasi
brazil
besid
neg
serolog
ifat
other
addit
effect
approach
perform
aim
rule
leishmania
infect
spray
kennel
ufop
pyrethroid
insecticid
protect
extens
throughout
appropri
secur
stainless
steel
gauz
recommend
brazilian
ministri
healthi
anim
treat
within
four
experiment
group
control
group
c
n
receiv
ml
steril
salin
ii
sap
group
n
receiv
mg
saponin
propos
borjacabrera
et
al
santo
et
al
ml
steril
salin
iii
sal
group
n
receiv
sge
prepar
five
acini
salivari
gland
l
longipalpi
ml
steril
salin
iv
lbsal
group
n
receiv
g
leishmania
braziliensi
promastigot
protein
lb
prepar
describ
previous
plu
sge
ml
steril
salin
v
lbsapsal
group
n
receiv
g
lb
plu
mg
saponin
togeth
sge
ml
steril
salin
type
saponin
use
quilaja
saponaria
molina
extract
commerci
sigma
chemic
co
st
loui
mo
usa
case
anim
receiv
three
subcutan
inject
right
flank
interv
week
veterinarian
check
anim
throughout
cours
studi
also
provid
full
medic
support
requir
dog
monitor
particularli
close
week
follow
inject
gener
toler
vaccin
establish
overal
evalu
includ
rectal
temperatur
measur
health
anim
local
toler
determin
direct
visual
examin
lesion
observ
measur
h
interv
period
h
inject
sampl
ml
peripher
blood
collect
jugular
vein
dog
transfer
tube
contain
amount
edta
suffici
produc
final
concentr
mgml
blood
sampl
store
room
temperatur
h
prior
process
coulter
counter
miami
fl
usa
model
employ
order
determin
absolut
count
lymphocyt
sampl
immunogen
evalu
determin
antibodi
rais
sge
solubl
lysat
l
chagasi
antigen
slca
accord
convent
enzymelink
immunosorb
assay
elisa
well
maxisorp
tm
nalg
nunc
intl
rochest
ny
usa
micropl
coat
sge
concentr
one
pair
salivari
glandswel
slca
gwell
serum
sampl
ad
dilut
sgeelisa
slcaelisa
well
wash
peroxidaseconjug
goat
antidog
sheep
antidog
igg
bethyl
laboratori
inc
montgomeri
tx
usa
ad
dilut
igg
well
rewash
substrat
chromogen
ophenylenediamin
sigmaaldrich
co
st
loui
mo
usa
ad
absorb
record
nm
sgeelisa
nm
slcaelisa
multiskan
mcc
labsystem
helsinki
finland
automat
micropl
reader
western
blot
analysi
l
longipalpi
sge
perform
accord
publish
method
briefli
sampl
sge
contain
ca
g
protein
equival
pair
salivari
gland
l
longipalpi
submit
sdspage
nupag
tm
novex
bistri
gel
mm
invitrogen
carlsbad
ca
usa
transfer
nitrocellulos
membran
cut
strip
block
overnight
tri
hcl
buffer
ph
contain
mm
nacl
plu
nonfat
milk
incub
dog
serum
dilut
block
buffer
follow
incub
antidog
igg
alkalin
phosphatas
conjug
dilut
promega
madison
wi
usa
band
visual
addit
alkalin
phosphatas
substrat
promega
madison
wi
usa
unlabel
canin
monoclon
antibodi
mab
clone
clone
clone
use
indirect
immunofluoresc
procedur
pool
normal
rat
serum
dilut
employ
isotyp
control
fluorescein
isothiocyan
fitc
label
igg
sheep
antirat
polyclon
antibodi
use
secondari
antibodi
nonspecif
bind
secondstep
reagent
block
pool
normal
sheep
serum
phosphat
buffer
salin
pb
contain
foetal
bovin
serum
gibco
grand
island
ny
usa
fitclabel
mous
clone
iobla
phycoerythrin
pe
mous
clone
rpeconjug
mous
antimous
mhci
clone
rpeconjug
hamster
antimous
armenian
clone
mab
use
direct
immunofluoresc
procedur
order
determin
optim
dilut
assay
mab
titr
pb
contain
bovin
serum
albumin
sodium
azid
unlabel
mab
antimhci
mab
purchas
serotec
oxford
uk
immunotech
co
marsel
franc
bd
bioscienc
pharmingen
franklin
lake
nj
usa
micropl
assay
immunophenotyp
canin
whole
blood
leukocyt
wbl
fresh
blood
sampl
peripher
blood
mononuclear
cell
pbmc
obtain
vitro
stimul
carri
describ
giunchetti
et
al
rei
et
al
flow
cytometr
measur
perform
facscan
instrument
becton
dickinson
moutain
view
ca
usa
interfac
appl
workstat
run
cellquest
softwar
becton
dickinson
data
acquisit
analysi
total
event
acquir
prepar
canin
wbl
select
basi
characterist
forward
fsc
side
ssc
lightscatt
distribut
follow
fsc
ssc
gain
adjust
lymphocyt
select
gate
fsc
versu
ssc
graph
fluoresc
evalu
fitc
pe
spectra
respect
singlehistogram
represent
monocyt
analys
fluoresc
intens
detect
singl
histogram
obtain
directli
ungat
leukocyt
marker
set
intern
control
nonspecif
bind
order
encompass
unlabel
cell
marker
use
analysi
data
given
anim
result
express
percentag
posit
cell
within
select
gate
cell
surfac
marker
present
bimod
distribut
semiquantit
analys
carri
cell
surfac
marker
mhci
exhibit
unimod
distribut
order
evalu
differenti
express
result
express
mean
fluoresc
channel
mfc
log
scale
data
also
express
absolut
count
order
allow
normal
valu
obtain
group
present
differ
overal
leukocyt
count
absolut
count
lymphocyt
monocyt
calcul
global
leukocyt
count
percentag
lymphocyt
monocyt
hematoscopi
absolut
count
lymphocyt
subset
monocyt
determin
respect
absolut
lymphocyt
count
percentag
fluoresc
posit
cell
within
lymphog
global
leukocyt
count
percentag
fluoresc
posit
cell
within
ungat
monocyt
pbmc
isol
ml
sampl
heparin
blood
layer
onto
ml
ficollhypaqu
densiti
gradient
histopaqu
sigma
chemic
co
centrifug
g
min
room
temperatur
separ
pbmc
resuspend
gibco
rpmi
medium
homogen
wash
twice
rpmi
centrifug
g
min
room
temperatur
homogen
final
resuspend
rpmi
cellsml
vitro
assay
carri
cell
cultur
medium
compris
rpmi
supplement
streptomycin
mgml
penicillin
uml
lglutamin
mm
heatinactiv
foetal
calf
serum
lymphoprolifer
assay
perform
flatbottom
tissu
cultur
plate
corn
new
york
ny
usa
well
contain
l
supplement
rpmi
medium
aliquot
l
pbmc
cellswel
ad
triplic
well
togeth
l
l
braziliensi
solubl
antigen
slba
gml
l
slca
gml
obtain
accord
rei
et
al
antigen
stimulu
assay
mitogen
stimulu
assay
l
aliquot
pbmc
cellswel
ad
triplic
well
togeth
l
phytohaemagglutinin
pha
gml
sigmaaldrich
chemi
gmbh
taufkirchen
germani
assay
mixtur
incub
humidifi
co
atmospher
c
mitogenicstimul
cultur
day
antigenicstimul
cultur
hthymidin
ci
sigma
chemic
co
ad
well
h
end
incub
period
cell
subsequ
harvest
onto
glass
fibr
filter
incorpor
radioact
determin
liquid
scintil
count
control
assay
prepar
exactli
employ
l
aliquot
pbmc
cellswel
l
rpmi
medium
replac
stimul
incub
appropri
time
prolifer
respons
express
term
mean
countsmin
triplic
well
whilst
stimul
index
calcul
mean
prolifer
respons
cultur
stimul
slba
slcamean
prolifer
respons
unstimul
cultur
order
investig
immunophenotyp
featur
pbmc
cultur
flatbottom
tissu
cultur
plate
costar
cambridg
usa
well
contain
l
supplement
rpmi
medium
aliquot
l
pbmc
cellswel
ad
triplic
well
togeth
l
slba
gml
l
slca
gml
control
assay
prepar
employ
l
aliquot
pbmc
cellswel
l
rpmi
medium
replac
stimul
incub
carri
humidifi
co
atmospher
c
day
pbmc
remov
immunophenotyp
supernat
collect
assay
describ
indirect
measur
product
nitrit
level
determin
serum
sampl
use
griess
reaction
reagent
employ
assay
purchas
sigmaaldrich
co
nitrat
reductas
uml
l
mm
nadph
l
mm
fad
l
ad
l
serum
dilut
distil
water
overnight
incub
c
sampl
deprotein
addit
volum
zinc
sulphat
gl
mixtur
centrifug
g
min
aliquot
l
griess
reagent
naphthylethylendiamin
dihydrochlorid
sulphanylamid
phosphor
acid
ad
supernat
follow
min
incub
dark
room
temperatur
absorb
measur
nm
automat
micropl
reader
sampl
assay
duplic
concentr
nitrit
determin
interpol
standard
curv
construct
plot
absorb
valu
standard
sodium
nitrat
solut
correspond
concentr
correl
plot
linear
rang
moll
data
express
mean
product
immedi
prior
applic
first
dose
vaccin
day
applic
first
dose
vaccin
day
applic
second
dose
vaccin
day
applic
third
dose
vaccin
statist
analys
perform
aid
prism
softwar
packag
prism
softwar
irvin
ca
usa
normal
data
establish
use
kolmogorovsmirnoff
test
oneway
analysi
varianc
anova
tukey
post
test
use
investig
differ
group
respect
humor
immun
respons
immunophenotyp
profil
student
ttest
employ
evalu
differ
mean
valu
determin
vitro
assay
humor
immun
respons
antisg
stimul
cultur
control
cultur
prepar
associ
phenotyp
featur
circul
leukocyt
phenotyp
featur
cell
prolifer
investig
use
pearson
rank
correl
case
differ
consid
signific
p
valu
vaccin
associ
pain
fever
hyperthermia
lymphadenopathi
gener
advers
reaction
furthermor
local
advers
reaction
observ
vaccin
anim
except
mild
indur
reaction
dog
vaccin
sap
lbsapsal
tabl
spite
presenc
nodul
dog
receiv
saponin
adjuv
sap
lbsapsal
result
format
ulcer
lesion
specif
antisg
humor
respons
four
group
experiment
anim
determin
immedi
prior
applic
first
dose
vaccin
day
applic
third
dose
vaccin
signific
p
increas
serum
level
antisg
total
igg
observ
dog
lbsapsal
group
compar
c
sal
lbsal
group
fig
left
panel
addit
analys
reveal
posit
associ
total
igg
p
r
igg
p
r
p
r
lbsapsal
group
fig
middl
panel
western
blot
analysi
fig
right
panel
indic
antibodi
produc
dog
vaccin
prepar
contain
sge
react
three
differ
protein
present
sand
fli
saliva
thu
serum
sampl
deriv
anim
lbsapsal
group
show
signific
reactiv
sge
protein
molecular
weight
kda
serum
sampl
sal
lbsal
lbsapsal
group
activ
kda
sge
protein
whilst
serum
sampl
sal
lbsapsal
group
activ
kda
sge
protein
fig
right
panel
serum
level
antil
chagasi
immunoglobulin
day
applic
first
dose
vaccin
day
applic
second
dose
vaccin
day
applic
third
tabl
local
alter
inoculum
region
measur
h
inocul
saponin
sap
candid
vaccin
compos
leishmania
braziliensi
promastigot
protein
plu
saponin
plu
sand
fli
salivari
gland
extract
lbsapsal
anim
code
nodul
size
cm
fig
signific
increas
antil
chagasi
total
igg
observ
anim
lbsapsal
group
compar
c
sap
group
furthermor
vaccin
lbsapsal
elicit
higher
level
p
antil
chagasi
total
igg
compar
c
sap
sal
lbsal
treatment
group
interestingli
comparison
c
sap
sal
group
ratio
significantli
higher
lbsal
group
lbsal
lbsapsal
group
immunophenotyp
profil
peripher
blood
dog
treat
differ
vaccin
fig
reveal
signific
increas
number
circul
tlymphocyt
anim
vaccin
lbsal
lbsapsal
compar
c
sap
sal
group
addi
tional
lbsal
group
present
higher
p
tcell
count
compar
sap
sal
group
circul
tlymphocyt
major
tcell
subset
contribut
enhanc
tlymphocyt
count
lbsapsal
profil
context
increas
p
tcell
count
observ
lbsapsal
group
compar
respect
c
sap
sal
lbsal
group
c
sap
sal
group
similarli
blymphocyt
count
exhibit
signific
increas
lbsapsal
group
compar
c
sap
sal
lbsal
group
although
signific
decreas
number
bcell
lbsal
group
compar
c
group
valu
time
period
consid
fig
right
panel
posit
correl
p
r
tcell
bcell
appar
lbsapsal
group
order
investig
reactiv
pbmc
antigen
vaccin
compon
l
braziliensi
slba
etiolog
agent
vl
l
chagasi
slca
memori
lymphoprolif
immun
respons
evalu
vitro
stimul
assay
whilst
signific
increas
p
stimul
indic
compar
observ
presenc
stimuli
lbsapsal
group
sal
group
display
signific
decreas
p
fig
upper
panel
furthermor
compar
analys
differ
treatment
group
show
signific
reduct
cell
reactiv
slca
sal
group
compar
c
group
contrast
lbsapsal
group
exhibit
higher
p
lymphoprolif
reaction
slba
compar
sap
sal
lbsal
group
slca
compar
c
sap
sal
lbsal
group
compar
analysi
immunophenotyp
profil
control
stimul
cultur
conduct
order
identifi
major
cell
popul
induc
left
middl
panel
depict
immunophenotyp
profil
peripher
blood
leukocyt
show
absolut
count
cell
determin
prior
first
dose
day
first
dose
day
second
dose
day
third
dose
signific
differ
p
comparison
control
c
sap
sal
lbsal
group
indic
respect
letter
b
c
right
panel
display
correl
circul
lymphocyt
lbsapsal
group
r
correl
index
vitro
slba
slca
data
reveal
higher
p
frequenc
tcell
lbsapsal
group
contrast
sap
group
present
decreas
frequenc
bcell
presenc
slba
slca
compar
nonstimul
control
cultur
fig
middl
panel
furthermor
attempt
determin
whether
immunophenotyp
featur
pbmc
cultur
subject
antigenstimul
vitro
associ
specif
cell
profil
level
associ
cell
type
prolifer
within
five
group
analys
fig
lower
panel
respect
sal
group
neg
correl
tcell
prolifer
observ
cultur
stimul
slba
p
r
slca
p
r
contrast
lbsapsal
group
exhibit
posit
correl
tcell
prolifer
cultur
stimul
slba
p
r
slca
p
r
regard
search
apc
dog
vaccin
lbsapsal
observ
number
circul
monocyt
higher
p
group
compar
sal
group
fig
upper
left
panel
alongsid
increas
monocyt
count
lymphocyt
activ
statu
lbsapsal
group
exhibit
increas
p
mean
fluoresc
channel
level
gate
lymphocyt
compar
c
sal
group
fig
upper
middl
panel
cell
surfac
marker
mhci
compar
c
group
fig
upper
right
panel
addit
lbsal
group
show
reduct
p
express
mhci
lymphocyt
compar
c
sal
group
correl
analysi
employ
investig
relationship
increas
monocyt
follow
improv
lymphocyt
activ
statu
mhci
lbsapsal
group
fig
middl
panel
interestingli
increas
count
monocyt
posit
correl
lymphocyt
activ
profil
respect
differenti
express
p
r
mhci
p
r
investig
reveal
posit
correl
lbsapsal
group
lymphocyt
express
p
r
data
point
connect
event
apc
lymphocyt
activ
statu
also
among
lymphocyt
activ
profil
marker
immun
lbsapsal
agreement
find
observ
dog
lbsapsal
group
display
higher
monocyt
count
also
exhibit
highest
level
express
mhci
lymphocyt
fig
middl
right
panel
order
identifi
apc
contribut
correl
analys
perform
specif
vitro
antigen
stimul
fig
lower
panel
data
reveal
vaccin
sal
result
neg
correl
monocyt
vitro
cell
prolifer
cultur
stimul
slba
p
r
slca
p
r
contrast
treatment
lbsapsal
elicit
posit
correl
monocyt
vitro
cell
prolifer
cultur
stimul
slca
p
r
sinc
consid
play
key
role
mechan
mediat
elimin
intracellular
pathogen
upper
panel
signific
differ
p
respect
absolut
count
monocyt
mhci
express
lymphocyt
report
mfc
valu
indic
letter
c
comparison
control
c
sal
group
respect
middl
panel
display
correl
cell
count
mhci
lymphocyt
mhci
lymphocyt
lbsapsal
group
lower
panel
depict
correl
absolut
cell
count
vitro
cell
prolifer
count
per
minut
cpm
follow
stimul
slba
slca
r
correl
index
level
antimicrobi
oxid
produc
serum
sampl
determin
progress
higher
p
level
reactiv
radic
record
sera
lbsapsal
group
compar
c
group
compar
c
sap
sal
group
fig
addit
lbsal
group
present
increas
p
level
compar
c
sap
sal
group
natur
histori
cvl
lesion
characterist
diseas
similar
mani
respect
describ
human
vl
reason
canin
model
consid
offer
excel
system
applic
studi
concern
leishmaniasi
man
moreov
natur
histori
cvl
well
describ
particularli
respect
parasit
load
differ
tissu
immunopatholog
chang
relat
progress
clinic
form
whilst
data
valuabl
develop
tool
employ
evalu
chemotherapi
vaccin
cvl
current
treatment
strategi
fail
achiev
consist
parasitolog
cure
diseas
owe
presenc
latent
infect
cell
respect
canin
vaccin
may
repres
practic
effect
method
reduc
incid
human
vl
could
also
provid
basi
develop
similar
vaccin
human
number
vaccin
compris
molecularli
defin
subunit
obtain
recombin
methodolog
shown
exhibit
degre
effect
experiment
leishmaniasi
especi
murin
model
approach
may
howev
accur
reflect
efficaci
dog
sinc
vaccin
design
protect
dog
clearli
develop
use
canin
model
sinc
saponin
previous
use
lasri
et
al
immun
dog
leishmania
promastigot
vaccin
inclus
adjuv
fml
formul
shown
strong
immunogen
dog
moreov
remark
result
obtain
follow
antigen
deriv
parasit
cultur
excretedsecret
antigen
vaccin
dog
kill
parasit
vaccin
demonstr
immunogen
studi
well
challeng
l
chagasi
show
success
vaccin
cvl
still
possibl
addit
field
assay
use
fml
antigen
purifi
excretedsecret
antigen
l
infantum
demonstr
encourag
efficaci
result
aim
improv
immunoprotect
vl
develop
vaccin
contain
compon
present
saliva
sand
fli
saliva
suggest
potenti
approach
control
leishmania
infect
major
consensu
l
chagasil
infantum
antigen
display
potent
immunosuppress
potenti
would
deleteri
immunoprotect
cvl
sever
studi
report
potenti
l
chagasi
antigen
trigger
immunosuppress
block
vitro
lymphoprolif
respons
leishmania
antigen
well
synthesi
proinflammatori
cytokin
antigenpres
cell
use
purifi
l
donovani
l
infantum
antigen
also
propos
overcom
immunosuppress
effect
l
chagasi
antigen
accord
giunchetti
et
al
studi
includ
clinic
trial
vaccin
candid
cvl
immunoprofilaxi
conduc
use
either
l
amazonensi
l
braziliensi
l
major
antigen
previou
studi
group
demonstr
l
braziliensi
antigen
potent
role
protect
l
chagasi
infect
dog
unpublish
data
therefor
critic
question
screen
develop
antileishmani
vaccin
cvl
defin
leishmania
antigen
adjuv
system
elicit
favour
sustain
cytokin
environ
vivo
consid
import
immunoprophylaxi
strategi
control
leishmaniasi
lack
studi
concern
cellular
humor
event
occur
vaccin
attempt
evalu
immun
respons
promis
new
vaccin
candid
cvl
compos
kill
l
braziliensi
vaccin
plu
saponin
salivari
gland
extract
l
longipalpi
lbsapsal
assess
inform
essenti
prerequisit
understand
mechan
relat
immunogen
elicit
candid
vaccin
context
describ
first
work
use
sand
fli
salivari
gland
vaccin
dog
repres
import
step
obtain
effect
vaccin
canin
viscer
leishmaniasi
gener
advers
reaction
occur
follow
immun
lbsapsal
local
advers
reaction
observ
minim
compris
mild
indur
without
format
ulcer
lesion
presenc
local
reaction
may
associ
use
saponin
adjuv
although
saponin
known
induc
develop
strong
tlymphocyt
cytotox
employ
adjuv
sever
veterinari
vaccin
whilst
nonspecif
immun
reaction
swell
nodul
format
loss
pelag
site
inject
anorexia
apathi
vomit
diarrhoea
report
present
studi
overal
toler
candid
vaccin
dog
appear
adequ
vaccin
lbsapsal
alon
elicit
product
elev
level
antisaliva
total
igg
whilst
lower
amount
antisg
immunoglobulin
isotyp
observ
sal
lbsal
group
suggest
critic
role
saponin
adjuv
induc
antisaliva
humor
respons
posit
correl
antisaliva
immunoglobulin
isotyp
especi
indic
mix
immun
respons
follow
vaccin
lbsapsal
moreov
suggest
mix
antisaliva
respons
involv
compon
human
subject
may
help
establish
antiimmun
l
chagasi
respons
addit
western
blot
experi
show
predomin
recognit
protein
molecular
weight
kda
particularli
follow
lbsapsal
vaccin
accord
valenzuela
et
al
cdna
salivari
gland
sand
fli
code
kda
polypeptid
show
strong
similar
angiotensin
convert
enzym
ace
anophel
gambia
drosophila
melanogast
chicken
human
howev
function
sand
fli
saliva
protein
peptidas
remain
elucid
kda
antisaliva
immunoglobulin
yet
detect
sera
human
dog
vl
kda
saliva
protein
previous
report
apyras
relat
potent
antiplatelet
factor
display
l
longipalpi
phlebotomu
papatasi
addit
kda
protein
describ
saliva
l
longipalpi
p
papatasi
p
ariasi
p
argentip
p
duboscqi
yellowrel
protein
consid
one
abund
protein
found
sand
fli
saliva
kda
protein
propos
vaccin
candid
control
l
chagasi
sera
asymptomat
symptomat
dog
area
endem
vl
present
antisaliva
immunoglobulin
recogn
saliva
protein
molecular
weight
kda
protein
identifi
respect
protein
member
yellow
protein
famili
propos
candid
develop
multicompon
vaccin
dog
major
saliva
protein
recogn
accord
western
blot
analysi
sera
human
subject
present
antisaliva
igg
antibodi
antileishmania
delay
type
hypersensit
dth
respons
molecular
weight
kda
similar
observ
immun
lbsapsal
addit
posit
associ
propos
antisaliva
igg
antibodi
antileishmania
dth
respons
suggest
presenc
antisaliva
immunoglobulin
link
develop
cellmedi
immun
leishmania
respect
present
find
indic
lbsapsal
vaccin
elicit
improv
antileishmania
immun
present
studi
higher
amount
antileishmania
total
igg
higher
ratio
display
lbsapsal
group
compar
group
similarli
demonstr
dog
immun
kill
leishmania
vaccin
present
higher
antibodi
product
second
vaccin
indic
possibl
associ
isotyp
product
cellular
immun
respons
import
mention
associ
igg
subtyp
immun
respons
term
phenotyp
straightforward
dog
find
immunoglobulin
isotyp
suggest
mix
immun
respons
trigger
lbsapsal
vaccin
analysi
circul
leukocyt
immunophenotyp
evalu
employ
order
assess
cellular
profil
follow
differ
vaccin
treatment
intens
antileishmania
humor
immun
respons
exhibit
lbsapsal
group
synchron
increas
number
circul
bcell
follow
first
immun
result
differenti
plasmacyt
higher
level
immunoglobulin
secret
describ
previous
dog
immun
crude
leishmania
antigen
addit
posit
correl
tcell
bcell
suggest
possibl
cooper
activ
humor
immun
respons
lbsapsal
group
higher
count
circul
bcell
previous
associ
resist
profil
cvl
addit
immun
lbsal
lbsapsal
elicit
increas
number
tlymphocyt
peripher
blood
howev
amplif
relat
tcell
subset
tcell
lbsapsal
group
recent
decreas
circul
tcell
count
report
dog
immun
crude
antigen
plu
bacillu
bcg
adjuv
contrast
anoth
studi
dog
immun
l
braziliensi
plu
saponin
adjuv
reveal
increas
number
circul
tcell
cvl
increas
count
circul
tcell
describ
major
phenotyp
featur
asymptomat
diseas
dog
bear
low
parasit
load
addit
increas
count
circul
tcell
associ
resist
marker
pattern
vaccin
leishmania
thu
find
support
hypothesi
immun
lbsapsal
elicit
increas
tlymphocyt
play
central
role
protect
immun
leishmania
infect
suggest
previous
cvl
evalu
activ
marker
veterinari
immunolog
new
approach
support
sever
investig
recent
propos
mhci
mhcii
may
appropri
lymphocyt
activ
marker
dog
context
close
correl
apc
evalu
monocyt
lymphocyt
activ
statu
could
demonstr
follow
lbsapsal
immun
interestingli
earli
increas
monocyt
lbsapsal
group
follow
higher
express
mhci
lymphocyt
shown
connect
event
known
upregul
mhci
ii
relat
presenc
addit
largest
apc
count
associ
highest
express
mhci
lymphocyt
suggest
associ
could
repres
interact
innat
adapt
immun
respons
reflect
improv
activ
statu
immun
lbsapsal
aim
determin
whether
candid
vaccin
would
activ
pbmc
vitro
antigen
stimul
stimul
indic
antigenspecif
immunophenotyp
pattern
investig
presenc
slba
slca
vitro
stimulu
pbmc
dog
immun
sal
present
lower
stimul
indic
compar
interestingli
neg
associ
demonstr
cell
reactiv
tlymphocyt
monocyt
follow
vitro
stimul
sal
group
data
support
hypothesi
sal
treatment
inhibit
monocyt
promot
tlymphocyt
activ
induct
cell
prolifer
fact
previous
describ
titu
saliva
l
longipalpi
suppress
develop
tcellspecif
sheep
red
blood
cell
srbc
prolif
respons
mice
immun
srbc
antigen
contrast
vitro
cultur
pbmc
deriv
lbsapsal
group
stimul
slba
slca
increas
lymphoprolifer
activ
accompani
higher
frequenc
tcell
result
support
hypothesi
tcell
play
protect
role
mechan
control
parasit
leishmania
lbsapsal
treatment
associ
antigenspecif
immun
respons
antigen
etiolog
agent
cvl
moreov
lymphoprolif
respons
lbsapsal
group
posit
associ
apc
tcell
follow
vitro
stimul
slca
slba
slca
respect
find
indic
stimul
antigenspecif
tcell
subset
follow
lbsapsal
immun
could
contribut
improv
cellular
immun
respons
l
chagasi
infect
sinc
key
compon
product
level
nitrit
determin
serum
differ
immun
group
result
show
progress
higher
product
level
confirm
potenti
resist
profil
leishmania
infect
follow
lbsapsal
vaccin
result
present
studi
provid
support
continu
develop
vaccin
base
whole
parasit
approach
vaccin
attract
term
safeti
stabil
product
compar
purifi
subunit
prepar
dna
vaccin
moreov
kill
vaccin
exhibit
greater
divers
antigen
repertoir
potenti
activ
stronger
cellular
respons
mainli
tlymphocyt
compar
purifi
subunit
prepar
dna
vaccin
addit
inclus
sand
fli
saliva
extract
vectorbas
vaccin
appear
advantag
virtu
potenti
neutral
antihaemostat
immunomodulatori
effect
arthropod
saliva
serv
enhanc
abil
pathogen
establish
infect
host
present
studi
sand
fli
saliva
extract
combin
kill
leishmania
vaccin
saponin
elicit
strong
immunogen
increas
antisaliva
antileishmania
immunoglobulin
isotyp
togeth
higher
count
circul
tlymphocyt
slcaspecif
tlymphocyt
high
product
conclus
lbsapsal
vaccin
elicit
potenti
immun
activ
statu
potenti
compat
effect
control
etiolog
agent
cvl
investig
focu
efficaci
lbsapsal
vaccin
protect
experiment
challeng
l
chagasi
